№ 299 29 filings · 2021-09-03 → 2026-03-26

RENALYTIX PLC

RENX

Health Care Share price 4.15p Market cap £18m Overall fit 180 /1000

Minimal genuine AI-receiver exposure (uses ML but is a diagnostic testing service, not a picks-and-shovels AI beneficiary); high theoretical operating leverage but no evidence revenue is materialising; valuation only fair, not cheap; downside protection is weak given going-concern uncertainty and chronic dilution. Poor fit for the strategy.

Fair value range 2p–6p Mid case · £17m

Absolute upside -6.3% vs current market cap

Conviction 2/5 confidence in fair call

Supports the call

Recent (Feb-2026) quantitative FY26 revenue guidance provides a near-term anchor
Balance sheet and going-concern position clearly disclosed
Regulated asset with FDA + Medicare reimbursement at a known $950 price

Limits the call

Value depends entirely on a national distribution deal of unknown timing/terms
Further equity dilution is highly likely but size/price unknowable

Methodology

EV/forward-sales multiple with probability-weighted dilution scenarios

In one line · bull case

Uniquely regulated diagnostic asset with real operating leverage if a national US distribution deal materialises in 2026 — but valuation only fair, not cheap, given track record.

In one line · biggest risk

Cash runway is under a year at current burn and a further heavily-dilutive equity raise is virtually certain before the commercial thesis has a chance to play out.

Drivers

AI beneficiary 25 /100

Uses ML in its prognostic algorithm and markets itself as AI-enabled, but core value is a regulated diagnostic test — not a picks-and-shovels AI beneficiary.

Operating leverage 65 /100

High theoretical leverage — fixed cost base c.$16m, gross margin ~50%, new lab designed to scale volumes without fixed-cost growth — but only valuable if revenue delivers.

Earnings vs expectations 10 /100

Repeated multi-year guidance cuts — FY26 revenue guidance cut from $8.4m to $4m within five months (Sept-2025 to Feb-2026).

Growth momentum 40 /100

Revenue growing from a tiny base ($3.0m FY25 → $4m FY26 guide) but decelerating vs prior expectations.

Moat 45 /100

FDA De Novo + Medicare reimbursement + KDIGO guideline inclusion create a moderate regulated moat, but adoption remains nascent.

Earnings quality 40 /100

Persistent losses, complex convertible-debt fair-value accounting, and repeated impairments — quality is low.

Management quality 20 /100

Three consecutive material downgrades to outer-year guidance and serial dilutive fundraising at progressively lower prices point to weak forecasting discipline.

Cyclicality 15 /100

Healthcare/diagnostics — largely defensive and non-cyclical.

Leverage 45 /100

Convertible bond $3.8m host + $0.5m derivative vs $3.4m cash — net leverage low in absolute terms but going-concern uncertainty flagged by auditors.

Value-trap signals · 5

Three consecutive years of missed outer-year revenue guidance
Share count expanded ~6x since 2022 through repeated deep-discount placings
Going-concern material uncertainty flagged by auditors
Cash of only $3.4m against $14m annual burn — funding cliff within ~6-9 months
Convertible bond dilution overhang (conversion price $0.30, PIK interest at 7.5%)

RENALYTIX PLC (RENX) — Investment Research Note

Executive summary

Renalytix commercialises kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic blood test for diabetic kidney disease, sold in the US at $950/test. Across the five-year period covered, the company achieved regulatory and reimbursement milestones but has consistently and materially missed its own revenue guidance while diluting shareholders from ~74m to 437m shares. The single most important valuation issue today is that FY26 guidance was cut ~50% (from $8.4m to c.$4m in only five months), the balance sheet holds just $3.4m of cash against a $14m annualised cash burn, and the auditors flag material going-concern uncertainty 2026-03 half-year report.

Fair value estimate

Range: 2p – 6p per share (mid ~4p) → implied market cap £9m – £26m (mid ~£17m)
Current mkt cap £16.8m at 4.47p → ~0% central upside; range −55% to +34%.

Methodology: Blended EV/forward-sales multiple + probability-weighted scenarios (I do not use DCF because the business is loss-making with no line of sight to positive FCF).

Key assumptions:

FY26 revenue $4m (per revised February 2026 guidance), FY27 $6–10m (I do NOT use the Sept-2025 $19m guidance — that guidance was withdrawn de facto by the Feb-2026 cut).
EV/Sales 3–4x on FY27 revenue = £14–24m equity value (net debt roughly zero after Sept-25 raise and bond conversion).
Discount for dilution risk: at current burn ($14m/yr) and cash ($3.4m), another equity raise is highly likely within 6–9 months. A £5–10m raise at 3–5p would add 15–30% more shares.
Downside scenario (30% weight): failure to sign distribution deal → further dilution or wind-down → 1–2p.
Upside scenario (20% weight): national distribution deal signed in 2026, FY27 revenue $15m+ → 8–12p.

The mid-point sits close to today's price — RENX appears roughly fairly valued, not obviously cheap.

Sector context

Health Care / Diagnostics (AIM). This is a sub-scale, pre-profit medtech name — quality and cash generation are well below sector-typical peers. Nearest listed comps: Verici Dx (VRCI, LSE) — sister company spun out of RENX, similar profile; Oxford BioDynamics (OBD, AIM); PredictImmune (PRIM, private/AIM). All share the "regulated diagnostic + slow adoption + repeated fundraising" pattern.

Investment thesis (3 bullets)

Unique regulated asset. Only FDA De Novo–authorised, Medicare-reimbursed ($950/test) early-stage DKD prognostic; recommended in KDIGO international guidelines; addressable US population ~14–15m diabetic-kidney patients 2026-03 half-year; 2025-03 half-year.
Structural operating leverage if revenue materialises. New Utah lab is designed to cut fixed cost per test as volume scales; management targets >$1m of 5-year opex savings; gross margin is already ~50% and would expand meaningfully at $10m+ revenue 2026-02 trading update.
Optionality from strategic distribution. Tempus AI collaboration and stated intent to sign a national US distribution partnership in CY 2026 could unlock the addressable market without further capex; a deal, if signed on reasonable terms, would materially re-rate the equity 2026-03 half-year.

Key risks (3 bullets)

Guidance credibility is broken. In September 2025 mgmt guided FY26/27/28 = $8.4m / $19m / $42m; five months later FY26 was cut to $4m 2025-09 revised guidance; 2026-02 trading update. Every prior multi-year forecast (Oct-2024 $3.2m→$8.5m→$17.5m) has also been missed on the outer years.
Going concern uncertainty & funding cliff. Auditors flag material uncertainty; cash was $6.1m at 31 Dec 2025 but only $3.4m currently vs. ~$14m annual cash burn — a further dilutive raise within 6–9 months is highly likely 2026-03 half-year.
Chronic dilution. Share count has risen ~6x since 2022 (74m → 437m) through repeated deep-discount placings (20p → 9p → 9.5p) and bond-for-equity conversion; the convertible bond has a $0.30/share conversion feature and interest accrues PIK at 7.5% 2024-09 placing; 2025-09 placing; 2026-03 half-year.

Operating leverage

The business has a theoretically high operating-leverage profile: gross margin is ~50% on de-minimis revenue ($1.6m H1 FY26 revenue, $0.8m COGS), and administrative costs of $7.9m/half-year are largely fixed (employee costs $4.4m, IT/marketing/insurance $1.5m, professional fees $0.6m) 2026-03 half-year. The new lab is explicitly designed to hold fixed costs flat while capacity scales. If revenue grew from the current $4m run-rate to $15–20m, incremental contribution margin should be 60–75% — a 10-20% revenue beat above expectations would drop disproportionately to operating profit. The problem is that revenue has not grown as promised; the theoretical operating leverage is only valuable if the top-line delivers, and the last four years of guidance misses suggest low near-term conviction.

Value-trap signals

Repeated multi-year guidance misses (three consecutive cuts to outer-year revenue).
Serial equity dilution at progressively lower prices.
Persistent going-concern flag across multiple reporting periods.
Auditor change (EY → PKF Littlejohn) coincident with NASDAQ delisting/cost-cutting.
Related-party transactions (Icahn School of Medicine at Mount Sinai) that shifted from paid real-world-evidence contract to third-party commercial billing at exactly the point commercial revenue was needed.
Revenue transition to a $4m target after guidance had been raised to $8.4m only 5 months earlier.

Earnings vs. expectations

Pattern across the covered period: consistent misses on the outer years, meets/slight-beats on the near-term. October 2024: FY25 guided $3.2m → delivered $3.0m (modest miss); FY26 guided $8.5m → running to $4m (massive miss); FY27 originally $17.5m, raised to $19m in Sept-2025, now looks unattainable on current trajectory. There is no visible analyst consensus in the filings — the Company is under-covered and management guidance is the anchor. The only clean "beat" was Q3 FY25 (April 2025) with 20% QoQ growth "in line" with expectations. Overall pattern: near-term realism, outer-year over-promising.

Conviction

Conviction: 2 (low).
Anchoring factors: (1) mgmt has provided quantitative FY26 revenue guidance twice in six months, giving me a defensible near-term revenue anchor; (2) the balance-sheet and going-concern position is unambiguous. Limiting factors: (1) the entire investment case hinges on a national distribution partnership whose timing and terms are unknowable from the filings; (2) further dilution is virtually certain, but its size and price are unknown, making per-share fair value highly sensitive. Any fair-value estimate for a company of this profile carries a wide error band.

Filings consulted · 32

Every document the LLM read for this note. Click any row to open the source.